Compare LAC & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAC | COLL |
|---|---|---|
| Founded | 2023 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | N/A | 2015 |
| Metric | LAC | COLL |
|---|---|---|
| Price | $5.16 | $48.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $5.50 | ★ $47.50 |
| AVG Volume (30 Days) | ★ 14.5M | 515.8K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.63 |
| Revenue | N/A | ★ $757,067,000.00 |
| Revenue This Year | N/A | $26.35 |
| Revenue Next Year | N/A | $3.67 |
| P/E Ratio | ★ N/A | $29.92 |
| Revenue Growth | N/A | ★ 26.34 |
| 52 Week Low | $2.31 | $23.23 |
| 52 Week High | $10.52 | $49.16 |
| Indicator | LAC | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 70.71 |
| Support Level | $5.12 | $46.15 |
| Resistance Level | $5.61 | $49.16 |
| Average True Range (ATR) | 0.31 | 1.32 |
| MACD | 0.04 | -0.16 |
| Stochastic Oscillator | 51.60 | 92.11 |
Lithium Americas is a pure-play lithium producer. Following a deal with the US government, the firm will own 59% of one resource, Thacker Pass, which is located in northwest Nevada, with automaker General Motors owning 36% and the US government owning 5%. Thacker Pass is under construction and expected to begin production in 2028. Thacker Pass is one of the largest known lithium resources in the world. The project would be the first clay-based asset to enter production, and we estimate it will be in bottom half of the global cost curve. Management plans to develop Thacker Pass into a fully integrated lithium production site, with downstream refining capabilities on site, and will sell into the lithium chemical market.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.